Camizestrant

Generic Name: Camizestrant

Clinical Trials

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

Phase 3

Active, not recruiting

Conditions: ER-Positive HER2-Negative Breast Cancer

Interventions: Drug: Anastrozole
Drug: AZD9833
Drug: Anastrozole placebo
Drug: AZD9833 placebo
Drug: Palbociclib
Drug: Luteinizing hormone-releasing hormone (LHRH) agonist

First Posted Date: 2021-01-15

Last Posted Date: 2025-03-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 1370

Registration Number: NCT04711252

Locations: 🇬🇧
Research Site, Surrey, United Kingdom

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Phase 1

Recruiting

Conditions: Ovarian Cancer
Colorectal Cancer
Endometrial Cancer
Small Cell Lung Cancer Only in Module 5
Breast Cancer
Pancreatic Cancer
Prostate Cancer
Additional Indications Below for Module 4 and 5
Non-small Cell Lung Cancer
Bladder Cancer

Interventions: Drug: AZD5305
Drug: Paclitaxel
Drug: T- Dxd
Drug: Dato-DXd
Drug: Camizestrant
Drug: Carboplatin

First Posted Date: 2020-11-25

Last Posted Date: 2025-04-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 804

Registration Number: NCT04644068

Locations: 🇬🇧
Research Site, Sutton, United Kingdom

A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer

Phase 2

Completed

Conditions: HER2-negative Breast Cancer

Interventions: Drug: AZD9833

First Posted Date: 2020-10-19

Last Posted Date: 2025-01-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 135

Registration Number: NCT04588298

Locations: 🇬🇧
Research Site, Manchester, United Kingdom

A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer

Phase 1

Active, not recruiting

Conditions: ER+ HER2- Advanced Breast Cancer

Interventions: Drug: AZD9833

First Posted Date: 2020-09-09

Last Posted Date: 2025-05-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 10

Registration Number: NCT04541433

Locations: 🇯🇵
Research Site, Koto-ku, Japan

A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer

Phase 2

Active, not recruiting

Conditions: Advanced ER-Positive HER2-Negative Breast Cancer

Interventions: Drug: AZD9833
Drug: Fulvestrant

First Posted Date: 2020-01-02

Last Posted Date: 2025-04-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 240

Registration Number: NCT04214288

Locations: 🇬🇧
Research Site, Leicester, United Kingdom

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

Phase 1

Active, not recruiting

Conditions: ER+ HER2- Advanced Breast Cancer

Interventions: Drug: AZD9833 with capivasertib
Drug: AZD9833
Drug: AZD9833 with palbociclib
Drug: AZD9833 with everolimus
Drug: AZD9833 with ribociclib
Drug: AZD9833 with anastrozole
Drug: AZD9833 with abemaciclib

First Posted Date: 2018-08-06

Last Posted Date: 2025-04-02

Lead Sponsor: AstraZeneca

Target Recruit Count: 396

Registration Number: NCT03616587

Locations: 🇬🇧
Research Site, Sutton, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy